Long-Term Use of Semaglutide: Is It Safe? What the Evidence Says

When you are considering taking a medication for months or years, the long-term safety profile matters enormously. With semaglutide-based medications like Obeda now available in India, it is a fair and important question: what does the evidence actually say about long-term use?

The answer is more reassuring than many patients expect -- with some important nuances worth understanding.

Important: Always consult your healthcare provider before starting or continuing any long-term medication. This article is for informational purposes only.

How Much Long-Term Data Exists?

Semaglutide (Ozempic) was first approved for type 2 diabetes in 2017. That means there is now approximately 8-9 years of real-world global data on semaglutide use.

The landmark trials provide controlled data of up to about 3-4 years:

• SUSTAIN-6: 2-year cardiovascular outcomes trial in type 2 diabetes patients
• SELECT trial: cardiovascular outcomes trial in adults with overweight or obesity and established heart disease, without diabetes (median follow-up 41.8 months; published 2023)
• FLOW trial: kidney outcomes trial in type 2 diabetes and chronic kidney disease (median follow-up 41 months)
• STEP trials: 68 weeks to 2 years (STEP 5) of controlled weight management data

For a medication that has been in widespread global use since 2017-2018, the safety record to date is notably positive.

What the Long-Term Evidence Shows

Cardiovascular Safety: Strongly Positive

The SELECT trial (published NEJM 2023) was a landmark study. 17,604 adults aged 45 or older with overweight or obesity and established cardiovascular disease, but no diabetes, were followed for a median of about 3.5 years on semaglutide 2.4mg or placebo. The result:

• 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) compared to placebo
• No increase in cardiovascular risk from long-term semaglutide use

This was not a neutral safety signal -- it was a strongly positive cardiovascular outcome. For people with obesity and existing heart disease, semaglutide appears to protect the heart, not harm it.

Kidney Health: Protective

In SUSTAIN-6, new or worsening kidney disease (mainly persistent macroalbuminuria, a sign of kidney damage) was less common with semaglutide. The dedicated FLOW trial, in 3,533 adults with type 2 diabetes and chronic kidney disease, found semaglutide 1 mg reduced the risk of a combined outcome of major kidney decline, kidney failure or cardiovascular death by 24% compared with placebo. Ozempic is now approved in the US to reduce these risks in this group.

Long-term renal harm from semaglutide has not been demonstrated. The main kidney risk is short term: dehydration from severe vomiting or diarrhoea can cause acute kidney injury, so contact your doctor if you cannot keep fluids down.

Pancreatic Safety

Pancreatitis is a known, rare risk with GLP-1 medications and has been monitored closely since their introduction. Long-term trial data shows:

• Acute pancreatitis has been reported in semaglutide trials, but it is rare
• Pancreatic cancer has not been shown to be caused by semaglutide in the data available so far
• Patients with a personal history of pancreatitis should still discuss risk carefully with their doctor
• Severe stomach pain that does not go away, with or without vomiting and sometimes spreading to the back, can be a sign of pancreatitis: stop semaglutide and get urgent medical help

Thyroid Safety

Animal studies at very high doses showed thyroid C-cell tumours (medullary thyroid carcinoma) in rodents. This led to the contraindication for patients with a history of MTC or MEN2.

The prescribing information states that it is unknown whether semaglutide causes thyroid C-cell tumours, including medullary thyroid carcinoma, in humans, because the human relevance of the rodent findings has not been determined. Human studies so far have not shown a clear increase, but the evidence is still limited.

The US label carries a boxed warning, and semaglutide must not be used by people with a personal or family history of MTC or with MEN 2. Tell your doctor about a lump or swelling in the neck, trouble swallowing, persistent hoarseness or shortness of breath.

Eye Health in Diabetes

In SUSTAIN-6, diabetic retinopathy complications occurred in 3.0% of people on semaglutide compared with 1.8% on placebo, with a larger increase in those who already had retinopathy. Rapid improvement in blood sugar may play a part. People with diabetes, particularly with existing retinopathy, should have regular eye checks and report any change in vision.

Mental Health

A concern raised in 2023-2024 was whether GLP-1 medications could cause suicidal thoughts or depression. The European Medicines Agency and FDA both investigated this after preliminary reports. Both agencies concluded, based on available data, that there is no established causal link between semaglutide and suicidal ideation, and in January 2026 the suicidal behaviour and ideation warning was removed from the US Wegovy label. Anyone who has new or worsening low mood or thoughts of self-harm while on any medicine should still tell their doctor promptly, and seek urgent help for thoughts of suicide.

Gallbladder

Weight loss from any cause increases gallstone risk -- and semaglutide users do have a modestly elevated gallbladder event rate in trials. In the Wegovy weight-reduction trials in adults, gallstones (cholelithiasis) were reported by 1.6% of people on semaglutide injection vs 0.7% on placebo, and gallbladder inflammation (cholecystitis) by 0.6% vs 0.2%.

This is a real but modest risk. Pain in the upper right abdomen, fever, or yellowing of the skin or eyes should be checked by a doctor promptly. Patients with a history of gallbladder disease should discuss it with their doctor. For most patients, the cardiovascular and metabolic benefits far outweigh this gallbladder risk.

What We Do Not Yet Know

Scientific honesty requires acknowledging the limits of current data:

• Very long-term use (10-20+ years): The oldest human data is approximately 8-9 years. Ultra-long-term effects in some areas remain unknown.
• Use in younger age groups: Most trial data involved middle-aged adults. Wegovy is approved from age 12, but long-term data in adolescents and young adults are more limited.
• Emerging safety signals: Post-marketing surveillance is ongoing. New signals, if they emerge, will be added to prescribing information.

These gaps do not constitute evidence of harm -- they are simply the known limits of evidence accumulated to date on a relatively new medication class.

The Chronic Condition Framework

The most useful frame for thinking about long-term semaglutide use is the same frame used for other chronic disease medications.

We do not ask whether blood pressure medication is "safe long-term" and conclude it should only be taken for 6 months. We accept that hypertension is a chronic condition requiring ongoing treatment, and we monitor for side effects while continuing the treatment that provides benefit.

Obesity is similarly a chronic, relapsing condition. The World Obesity Federation and many national medical bodies now classify obesity as a chronic disease requiring chronic management. Stopping semaglutide typically leads to weight regain because the underlying condition has not been cured -- it has been managed.

Long-term use, with appropriate monitoring, is supported by the weight of current evidence for patients who continue to benefit from it.

What Monitoring Looks Like Long-Term

For patients on Obeda or another semaglutide long-term, your doctor will set the schedule. An example of what monitoring may include:

This is not burdensome -- it is standard chronic disease management.

How Weight Easy Supports Long-Term Patients

Long-term semaglutide use works best when lifestyle habits are built and maintained alongside the medication. Weight Easy's coaching, dietary guidance, and progress tracking are designed to support not just short-term results but the sustainable long-term management of weight and metabolic health.

If you are considering Obeda as a long-term treatment, the right support structure is what makes that commitment worthwhile. Weight Easy helps you stay consistent and keep track of side effects to discuss with your doctor.

The Bottom Line

Based on available evidence from 8+ years of global use and controlled trials of up to about 3-4 years, semaglutide has a reassuring long-term safety profile. Cardiovascular outcomes are improved, not worsened, and kidney benefit has been shown in people with type 2 diabetes and kidney disease. The known risks -- GI side effects, gallbladder events, rare pancreatitis, dehydration-related kidney injury and diabetic eye complications -- are well characterised, and the thyroid tumour question in humans is not fully settled.

For patients who need ongoing obesity management, current evidence supports long-term semaglutide use with appropriate monitoring. The evidence will continue to accumulate, and guidance should be updated accordingly.

Consult your healthcare provider before starting or continuing any long-term medication. Individual health profiles vary significantly.

Related Articles

• GLP-1 Drugs Before Surgery: What You Need to Stop and When
• GLP-1 Hair Loss: Why It Happens and What to Do
• What Happens When You Stop Ozempic?

Consult your healthcare provider before starting any medication.

Sources

• Ozempic prescribing information (US; SUSTAIN-6 and FLOW data): https://www.novo-pi.com/ozempic.pdf
• Wegovy prescribing information (US; SELECT data, gallbladder rates): https://www.novo-pi.com/wegovy.pdf
• MedlinePlus — semaglutide: https://medlineplus.gov/druginfo/meds/a618008.html
• STEP 1 semaglutide trial — PubMed: https://pubmed.ncbi.nlm.nih.gov/33567185/